ArticleCancer immunology, immunotherapy : CII1993
T cell killing of human colon carcinomas by monoclonal-antibody-targeted superantigens.
Article in Cancer immunology, immunotherapy : CII, 1993. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
9 citing papers in PubMed, 19 citations in OpenAlex.
- Gene therapy by membrane-expressed superantigen for alpha-fetoprotein-producing hepatocellular carcinoma.Gene therapy · 2006Article
- Superantigen-SEA gene modified tumor vaccine for hepatocellular carcinoma: an in vitro study.World journal of gastroenterology · 2004Article
- Metastasis-association of the rat ortholog of the human epithelial glycoprotein antigen EGP314.Oncogene · 1999Article
- Major histocompatibility complex class I molecule serves as a ligand for presentation of the superantigen staphylococcal enterotoxin B to T cells.Proceedings of the National Academy of Sciences of the United States of America · 1996Article
- Immunotherapy of human colon cancer by antibody-targeted superantigens.Cancer immunology, immunotherapy : CII · 1995Article
- Bacterial pyrogenic exotoxins as superantigens.Clinical microbiology reviews · 1995Review
- Co-stimulation with B7 and targeted superantigen is required for MHC class II-independent T-cell proliferation but not cytotoxicity.Immunology · 1993Article
- Monoclonal antibodies and superantigens: a novel therapeutic approach.Medical oncology and tumor pharmacotherapy · 1993Review
- Targeting of superantigens.Cell biophysicsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The bacterial superantigen staphylococcal enterotoxin A (SEA) induces T cell activation as well as directing activated T cells to kill major-histocompatibility-complex-class-II-expressing tumours such as freshly prepared leukemia cells. We now report that conjugates of SEA and the colon-carcinoma-reactive mAb C215 mediate T-cell-dependent killing of freshly isolated cells obtained from surgical specimens of human colon carcinomas. Cytotoxicity was observed at nanomolar concentrations of conjugate while no or very low effects were seen with the mAb C215 or SEA alone. Tumour-infiltrating lymphocytes (TIL) did not exert any cytotoxicity against conjugate-treated tumour cells immediately after isolation. In vitro culture of TIL with interleukin-2 and SEA resulted in SEA-mAb-conjugate-dependent killing of freshly isolated tumour cells. This suggests that mAb-SEA conjugates may be of potential use to target T lymphocytes, including TIL, against colon carcinoma cells in vivo.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.